Odyssey Health Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	3yrs

Recent management updates

Recent updates

CEO

Odyssey Health has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Joseph Redmond	Chairman	6.4yrs	US$546.00k	8.82% $ 310.3k
Ricky Richardson	Independent Director	3yrs	US$150.00k	0% $ 0
Bob Arnot	Member of Scientific Advisory Board	3yrs	no data	no data
Jerome Casey	Independent Director	4.7yrs	US$150.00k	0% $ 0
Dallas Hack	Member of Scientific Advisory Board	3.1yrs	no data	no data
Jeffrey Conroy	Director	1.3yrs	US$375.00k	0% $ 0
James Kelly	Member of Scientific Advisory Board	3.1yrs	no data	no data
James Linder	Member of Military Advisory Board	2.2yrs	no data	no data
Paul Toolan	Member of Military Advisory Board	2.2yrs	no data	no data
Timothy Szymanski	Member Of Military Advisory Board	2.1yrs	no data	no data

3.0yrs

Average Tenure

62yo

Average Age

Experienced Board: ODYY's board of directors are considered experienced (3 years average tenure).

Odyssey Health Management

Management criteria checks 1/4

Key information

Recent management updates

Odyssey Health, Inc. Appoints Jeffrey Conroy as Director

Odyssey Health, Inc. Announces Resignation of Jeffrey Conroy as Director

Odyssey Health, Inc., Annual General Meeting, Jan 12, 2023

Odyssey Health Inc. Announces Expansion of Executive Team

Odyssey Health, Inc. Names Vice Admiral (r) Timothy Szymanski to the Military Advisory Board

Odyssey Group International Announces Formation of Military Advisory Board

Recent updates

Odyssey Health, Inc. announced delayed 10-Q filing

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS

Odyssey Health, Inc. (OTCPK:ODYY) executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.

Odyssey Health, Inc. Appoints Jeffrey Conroy as Director

Odyssey Health, Inc. to Develop Intranasal Field- Deliverable Nerve Agent Antidote

Odyssey Health, Inc. Announces Resignation of Jeffrey Conroy as Director

Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development

Odyssey Health, Inc., Annual General Meeting, Jan 12, 2023

Odyssey Health Inc. Announces Expansion of Executive Team

Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug

Odyssey Health, Inc. Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II

Odyssey Health, Inc. Announces the Successful Completion of Safety Measures for Their Phase I Multi-Day Ascending Dosing (Mad) Clinical Trial

Odyssey Health, Inc. Announces Positive Results from its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion

Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug

Odyssey Health, Inc. Completes Safety Evaluation of Cohort I for Concussion Drug

Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug

Odyssey Health, Inc. Names Vice Admiral (r) Timothy Szymanski to the Military Advisory Board

Odyssey Group International Announces Formation of Military Advisory Board

Odyssey Group International, Inc. Continues Enrollment of its First in Kind Human Clinical Trial of its Proprietary Drug Compound Intended to Treat Concussion

Odyssey Group International, Inc. Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion

Odyssey Group International, Inc. Approves to Start Human Trial to Treat Concussion

Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial

Odyssey Group International Reports Achieving Drug Safety Standards for Clinical Trials of its Drug for Treating Concussion

Odyssey Group International, Inc. announced delayed 10-Q filing

Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion

Odyssey Group International, Inc. Announces the Completion of the Food and Drug Administration (FDA) Required Toxicology Studies Designed to Support Clinical Trials with Prv-002

Odyssey Group International Announces Completion of Novel Device for Nasal Delivery of Concussion Drug Candidate

Odyssey Group International, Inc. announced a financing transaction

Odyssey Group International, Inc. announced delayed annual 10-K filing

Odyssey Group International, Inc. announced that it expects to receive $10.6 million in funding from The EquiLux Group, LP, Lincoln Park Capital, LLC

CEO

Board Members

Average Tenure

Average Age